FDA-Approved IV Iron Formulations

Panelists discuss how modern FDA-approved intravenous iron formulations, including ferric carboxymaltose, ferumoxytol, and iron sucrose, offer improved safety profiles and more efficient iron delivery compared with older compounds, thanks to their more stable carbohydrate shells and controlled iron release mechanisms.

EP: 1.Background and Causes of Iron Deficiency Anemia

EP: 2.Pathophysiology of Iron Deficiency Anemia

EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia

EP: 4.Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia

EP: 5.Monitoring Patients With Iron Deficiency Anemia After Diagnosis

EP: 6.Oral vs IV Iron in Clinical Practice

Now Viewing

EP: 7.FDA-Approved IV Iron Formulations

Video content above is prompted by the following:

• Could you provide an overview of the FDA-approved IV iron formulations used in the treatment of IDA? Additionally, what are the structural differences between the older and newer IV iron formulations?

Related Videos

Related Content

Advertisement

January 30th 2025

Genetic Causal Link Found Between RA, Increased Fracture Risk

Brooke McCormick

A genetic causal link between rheumatoid arthritis (RA) and an increased risk of traumatic and osteoporotic fractures underscores the need for targeted prevention strategies.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 29th 2025

How FcRn Blockade Targets Myasthenia Gravis Autoantibodies

Maggie L. Shaw Katie Abouzahr, MD

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 28th 2025

Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases

Brooke McCormick

First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.

January 28th 2025

Prolonged Immigration Detention Tied to Poor Health, PTSD, and Mental Illness

Brooke McCormick

Prolonged immigration detention is significantly associated with worsened self-rated health, along with high rates of posttraumatic stress disorder (PTSD) and mental illness.

Related Content

Advertisement

January 30th 2025

Genetic Causal Link Found Between RA, Increased Fracture Risk

Brooke McCormick

A genetic causal link between rheumatoid arthritis (RA) and an increased risk of traumatic and osteoporotic fractures underscores the need for targeted prevention strategies.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

January 29th 2025

How FcRn Blockade Targets Myasthenia Gravis Autoantibodies

Maggie L. Shaw Katie Abouzahr, MD

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

January 28th 2025

Niraparib Extends PFS, Time to Next Treatment in Patients With EOC, Especially BRCA-Mutated Cases

Brooke McCormick

First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC), with the greatest benefit observed in those considered homologous recombination-deficient (HRd) and those with BRCA-mutated (BRCAm) tumors.

January 28th 2025

Prolonged Immigration Detention Tied to Poor Health, PTSD, and Mental Illness

Brooke McCormick

Prolonged immigration detention is significantly associated with worsened self-rated health, along with high rates of posttraumatic stress disorder (PTSD) and mental illness.